These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23092284)

  • 1. Discovery of small molecule fusion inhibitors targeting HIV-1 gp41.
    Zhou G; Chu S
    Curr Pharm Des; 2013; 19(10):1818-26. PubMed ID: 23092284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W; Lu L; Li W; Jiang S
    Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S; Zhao Q; Debnath AK
    Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
    Liu S; Jiang S
    Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
    J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
    Liu S; Wu S; Jiang S
    Curr Pharm Des; 2007; 13(2):143-62. PubMed ID: 17269924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
    Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
    PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
    Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
    J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.
    Ouyang W; An T; Guo D; Wu S; Tien P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):613-20. PubMed ID: 23308369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
    Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors.
    Jurado S; Moog C; Cano-Muñoz M; Schmidt S; Laumond G; Ruocco V; Standoli S; Polo-Megías D; Conejero-Lara F; Morel B
    J Mol Biol; 2020 Sep; 432(20):5577-5592. PubMed ID: 32822695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.
    Su S; Wang Q; Xu W; Yu F; Hua C; Zhu Y; Jiang S; Lu L
    AIDS; 2017 Apr; 31(7):885-894. PubMed ID: 28121713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
    Miyauchi K; Kozlov MM; Melikyan GB
    PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.